The potential of such a novel supporting concept of targeting the SMURF2-GSTP1 interaction to enhance the efficacy of ferroptosis-inducing treatments is particularly significant in cancer types where resistance to apoptosis is high and where therapies targeting other pathways, such as those mediated by GPX4, have shown limited effectiveness (Figure 3). Here, GSTP1 is linked to cancer.